




INNOCARE

诺诚健华



InnoCare Pharma (9969.HK) – 2022 Interim Results

August 2022

Disclaimer


These materials are for information purposes only and do not constitute or form part of an offer or invitation to sell or issue or the solicitation of an offer or invitation to buy or subscribe for securities of InnoCare Pharma Limited (the “Company”) or any of its holding company or subsidiaries in any jurisdiction. No part of these materials shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

The information or opinions contained in these materials has not been independently verified. No representation or warranty, whether expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information and opinions contained in these materials are provided as of the date of the presentation, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. The Company, any of its affiliates, directors, supervisors, senior managers, officers, employees, advisers and their respective representatives shall not have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from or in reliance upon any information contained or presented in or derived from these materials or otherwise arising in connection with these materials.

These materials contain statements that reflect the Company’s current beliefs and expectations about the future as of the respective dates indicated herein. These forward-looking statements are based on a number of assumptions about the Company’s operations and businesses and on factors beyond the Company’s control, and are subject to significant risks and uncertainties, and, accordingly, the actual results may differ materially from these forward-looking statements. You should not place undue reliance on any of such forward-looking information. The Company assumes no obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that emerge subsequent to such dates.

To Become
a **Global Biopharmaceutical Leader**
that Develops and Delivers
Innovative Therapies for Patients Worldwide

Oncology



Autoimmune

Our Therapeutic Focus

InnoCare Investment Highlights

1

Top-tier Founder & Management Team

- ✓ Experienced founders and strong management team with an excellent track record in drug discovery, clinical development, business development and commercialization

2

Fully-integrated Drug Innovation Platform

- ✓ In-house drug discovery platform and highly efficient clinical development team
- ✓ Well established sales force and novel drug manufacturing facilities

3

A Leading Hema-oncology Franchise

- ✓ Orelabrutinib launched in 2021 with accelerated growth following NDRL inclusion
- ✓ Differentiated approach to hard-to-treat B-cell lymphomas with CD-19, CD20xCD3, E-3 ligase, and BCL-2 molecules
- ✓ Focused and effective sales force expansion

4

Autoimmune Diseases Drugs Covering Both B cell and T cell Pathogenic Pathways

- ✓ Orelabrutinib - Partnered with Biogen in MS; completed Phase II in SLE with positive results and entering further trials
- ✓ Potential best-in-class TYK-2 inhibitors, ICP-332 entered Phase II and ICP-488 initiated Phase I trials
- ✓ A portfolio of compounds targeting different pathways offering a comprehensive coverage of autoimmune disease

5

Competitive Solid Tumor Portfolio

- ✓ Highly selective FGFR, TRK and SHP2 inhibitors in Phase I or II clinical studies in both China and U.S.
- ✓ Advanced solid tumor pipeline covering multiple promising targets i.e. potential first-in-class CCR8, bispecific antibodies

6

Strong Cash Position Providing Safety and Flexibility

- ✓ Continue to expand pipeline through internal and external opportunities
- ✓ M&A opportunities for assets and platforms
- ✓ A shares Listing to provide sufficient funding for growth and expansion

Transforming from Biotech to Biopharma

Snapshot of Achievements in 2022H1

Accelerated Commercialization

- Total revenue reached **RMB 246mn**, including **RMB 217mn of Orelabrutinib sales**, in 2022H1
- Rapid market penetration and hospital coverage after NRDL inclusion
- Tafasitamab 1st prescription landed in Hainan
- Commercial team in expansion

Business Development Progressing

- **Out-licensing:** Orelabrutinib in **MS with Biogen Phase II patient enrollment close to completion**
- **In-licensing:** Tafasitamab pivotal trial patient enrollment initiated in mainland China
- **Collaboration** projects with KeyMed entered clinical stage

Rapidly Maturing Pipeline

- Submitted NDA for WM and MZL
- **SLE moves to further clinical trial in China**
- **Orelabrutinib 1L DLBCL-MCD registrational Phase III trial commenced**
- **ICP-332 Phase II trials initiated in AD and Psoriasis**
- **ICP-488 Phase I initiated**
- **ICP-192 and ICP-723 well positioned** for registrational trials
- 3 NMEs entered clinical stage
- 11 clinical assets in total
- 30+ ongoing global clinical trials

Expanding Infrastructure

- Ready for commercial production of Orelabrutinib in our Guangzhou facility
- Biological drug R&D facility in Beijing

Solid Financial Position


- Over **RMB 5bn** net cash in hand
- CSRC approval obtained for STAR Board listing
- Cost sensitive and cost efficient culture

Commercialization Update

Strong Sales Ramp-up with Orelabrutinib

Robust Net Sales Growth¹

宜诺凯



Successful Commercialization Strategy

- Net sales achieved **RMB 217mn** in 2022H1
- Swift implementation of NRDL at local level
- Experienced and effective in-house commercial team
- Rapid coverage of hematology market in China:
 - Penetrated **260+** Cities
 - Covered **1,000+** Hospitals
 - Educated **5,000+** Doctors
- CSCO Diagnosis and Treatment Guidelines** recommended broad use: r/r CLL/SLL, r/r MCL, r/r DLBCL and PCNSL
- Substantial future growth potential:
 - Indication expansion
 - DOT enhancement
 - Extensive post market clinical studies to strengthen best-in-class profile
 - Tailored-access at different tiered cities

¹ **Indications:** r/r Mantle Cell Lymphoma ("MCL") and r/r Chronic Lymphocytic Leukemia/Small Cell leukemia ("CLL/SLL")

1 Major Program Update

Orelabrutinib (ICP-022) : Comprehensive Coverage in Hematology

- r/r WM NDA accepted by CDE in 2022H1 and site inspection ongoing
- r/r MZL NDA accepted by CDE in 2022H1
- 1L DLBCL - MCD registrational trial enrollment ongoing, promising real world study results posted at ASCO
- 1L CLL/SLL trial more than halfway through patient enrollment
- A comprehensive tool-kit including Orelabrutinib, Tafasitamab, ICP-B02 and ICP-490 offers us a unique position to tackle all stages of DLBCL patients with combination therapies


Drug	Target	Indication(s)	Worldwide Rights	Pre-clinical Development	IND	Phase I	Phase II	Phase III	Launched
ICP-022/ Orelabrutinib	BTK	r/r CLL/SLL		NDA approved: 25 Dec 2020					★
		r/r MCL		NDA approved: 25 Dec 2020					★
		r/r WM		NDA accepted by NMPA In 2022Q1					☑
		r/r MZL		NDA accepted by NMPA In 2022Q8					☑
		1L: CLL/SLL							🏆
		1L: MCL							🏆
		1L: DLBCL - MCD							🏆
		r/r MCL		US Development Status					🏆
		r/r CNSL							
		Combo w/ MIL-62 (basket)							

2 Major Program Update

Orelabrutinib (ICP-022) : SLE Phase II Positive Results Lead to Further Development



SRI-4 Response Rate at 12 Weeks




SLE Phase II Study Results¹

- SLE Responder Index ("SRI")-4 response rates increased in a dose dependent manner
- Trends of reduction in proteinuria level and improvement of immunologic bio-markers²
- The only BTKi ever shown efficacy in Phase II SLE trials
- Further trial protocol is under final discussion with the CDE

Worldwide Huge Unmet SLE Market Needs


(USD bn)



Source: Frost & Sullivan Analysis 2021

Unmet SLE Potential Market in China

(RMB bn)



Source: Frost & Sullivan Analysis 2021

Currency rate: USD1 :RMB6.7

¹ The Phase II trial evaluated the safety and efficacy of Orelabrutinib plus standard of care verse placebo plus standard of care ("SoC") in patients with mild to moderate SLE

² Reduced immunoglobulin G and increased complements C3 and C4 were observed

Current Status and Further Development

- Pivotal trial for r/r DLBCL initiated to support approval in mainland China
- 1st prescription landed in Hainan
- NDA submitted in Hong Kong
- NDA to be submitted in Macau, followed by pilot use in GBA
- Potential combination therapy with Orelabrutinib


Competitive Landscape: Selected Novel Therapy in r/r DLBCL

Company	Target	Therapy	Phase	ORR (%)	CR (%)	mDOR (m)	mPFS (m)	mOS (m)
Incyte/InnoCare	CD19	Tafasitamab + Lenalidomide	Approved ex-China	57.5	40	43.9	11.6	33.5
ADC Therapeutics	CD19 ADC	Loncastuximab tesirine	II	59	41	4.8	5.5	11.6
Roche	CD79b ADC	Polatuzumab vedotin + BR vs BR	II	45 vs 18	40 vs 18	12.6 vs 7.7	9.5 vs 3.7	12.4 vs 4.7
Amgen/Beigene	CD19/CD3	Blinatumomab	II	43	19	11.6	3.7	5.0
Regeneron/Zai Lab	CD20/CD3	Mosunetuzumab	Ib	35	19	N/A	N/A	N/A
Roche	CD20/CD3	Glofitamab	Ib	38	31	N/A	N/A	N/A
Others	BCL2	Venetoclax	I	18	12	N/A	1.0	8.0

Source: Frost & Sullivan Analysis

ICP-332 (TYK-2, JH1)

- Safe and well-tolerated, **no significant decrease of platelet and hemoglobin (JAK2-related AE) observed in Phase I studies**
- Demonstrated a dose proportional and favorable PK profile, no significant food effect observed
- Phase II trials initiated in atopic dermatitis and psoriasis



ICP-488 (TYK-2, JH2)

- An oral, potent and allosteric TYK2 inhibitor that selectively binds to the JH2 pseudokinase domain
- Favorable ADME and safety profile **with no activities on JAK1-3**
- Potential to show significant advantages in safety profiles verse other JAK family inhibitors
- Phase I first cohort completed in August 2022

Major Program Update


ICP-192: Promising Safety and Efficacy Seen in Phase II trials

ICP-192 (Gunagratinib, FGFR)

- Finished dose-escalation ranging from **2 mg to 26 mg** and **no DLT observed**
- Safe and well-tolerated in patients with advanced solid tumors
- **20 mg** showed **efficacy in cholangiocarcinoma patients** with **62.5% ORR** and **100% DCR**, data posted at **ASCO**
- **Well positioned to enter potential registrational trial in cholangiocarcinoma**
- Progressing Phase II trial in urothelial cancer **in China**
- Progressing basket trial, including gastric and head & neck cancer **in China, Australia** and **the U.S.**

A Glance at FGFR Mutation by Solid Tumor Types Worldwide


(No. of Patients '000)




ICP-723 (TRK)

- **2nd generation TRKi overcomes acquired resistance to 1st generation TRKi**
- **No DLTs** observed in Phase I (1-16 mg)
- Phase I study demonstrated favorable PK profile and anti-tumor activity
- **100% ORR** observed in various types of solid tumors carrying NTRK fusion at dosages of 4 mg and above
- Well positioned to enter potential registrational trial in China soon
- Study to expand potential use in adolescent and pediatric patients
- Clinical trial initiated in the U.S.

NTRK Gene Fusion Mutation is an Oncogenic Driver for a Variety of Cancer Types



Pre-clinical Results


ICP-723 showed excellent activities against TRK resistance mutations including gatekeeper, xDFG and solvent front mutations.

Other Program Update

Continuous Strong Flow of Early Stage Projects



Entering Phase I

- **ICP-B02 / CM355 (CD3 x CD20)**
 - First patient enrolled in Feb 2022 and Phase I trial ongoing in China
- **ICP-189 (SHP2)**
 - First patient enrolled in June 2022 and Phase I trial ongoing in China
- **ICP-033 (DDR1, VEGFR)**
 - First patient enrolled in March 2022 and Phase I trial ongoing in China
- **ICP-490 (E3-Ligase)**
 - IND approved in July 2022 and Phase I initiated in China



IND Being Approved

- **ICP-248 (BCL-2)**
 - IND submitted in June 2022 and accepted by CDE in July 2022
- **ICP-B05 / CM365 (CCR8)**
 - IND submitted in May 2022 and accepted by CDE in 2022Q2

Research & Development

Product Pipeline – Liquid Cancer

	Drug	Target	Indication(s)	Worldwide Rights	Pre-clinical Development	IND	Phase I	Phase II	Phase III	Launched
Liquid Cancer	ICP-022/ Orelabrutinib	BTK	r/r CLL/SLL		NDA approved: 25 Dec 2020					★
			r/r MCL		NDA approved: 25 Dec 2020					★
			r/r WM		NDA accepted by NMPA In 2022Q1					☑
			r/r MZL		NDA accepted by NMPA In 202208					☑
			1L: CLL/SLL							★
			1L: MCL							★
			1L: DLBCL - MCD							★
			r/r MCL		US Development Status					★
			r/r CNSL							
			Combo w/ MIL-62 (basket)							
	ICP-B04/ Tafasitamab	CD19	DLBCL/Hematology							★
	ICP-B02	CD3 x CD20	Hematology							
	ICP-490	E3 Ligase	Hematology		IND was approved in 202207					
	ICP-248	BCL-2	Hematology		IND was accepted by CDE in 202207					

★ Listed drug
 ★ Registrational trials
 ☑ NDA
 ■ Clinical Stage
 ■ Pre-clinical Stage
 ■ Commercial Product
 ■ Clinical Asset

Research & Development

Product Pipeline – Solid Tumors and Autoimmune Diseases



Listed drug



Registrational trials



NDA



Clinical Stage



Pre-clinical Stage



Commercial Product



Clinical Asset

Anticipated Milestones & Catalysts in Next 12 Months

Liquid Cancer	■ Orelabrutinib □ r/r WM NDA approval □ r/r MZL NDA approval □ Complete 1L DLBCL-MCD enrollment □ Complete 1L CLL/SLL enrollment □ Complete r/r MCL enrollment in U.S. ■ TafaTafasitamab (CD19) □ NDA approval in HK/Macau □ Commence pilot use in GBA □ Complete r/r DLBCL pivotal trial enrollment in China	Auto-immune Diseases	■ Orelabrutinib □ SLE further trial initiation in China □ MS Phase II global trial result □ ITP Phase II preliminary result ■ ICP-332 (TYK2 - JH1) □ Phase II in AD efficacy and safety result □ Global Phase II enrollment completed ■ ICP-488 (TYK2 - JH2) □ Complete Phase I trial
Solid Tumors	■ ICP-192 (FGFR) □ Expanding into iCCA registrational trial in China ■ ICP-723 (TRK) □ Initiate registrational trial in China ■ ICP-189 (SHP2) □ Phase I trial result ■ B05 (CCR8) □ Phase I commences first patient enrollment	Discovery	■ 2-3 NMEs entering clinical stage
		Capital Market	■ A share listing on STAR Board
		Production	■ Commence commercial production at Guangzhou site




Financial Update

Key Financials for 2022H1


Revenue

(RMB mn)




R&D Costs

(RMB mn)




Loss for the Period

(RMB mn)



Cash and Cash Equivalents¹

(RMB mn)



¹ Cash and cash equivalents = investments measured at fair value investments, cash and bank balance

² Net cash = cash balance – convertible loan – loans and borrowings – loans from a related party

科学驱动创新 患者所需为本

Science Drives Innovation for the Benefit of Patients
